PDHB drives the transcription of glycolysis-related genes and metabolic reprogramming by binding to the SLC2A1, GPI, and PKM2 promoters, thereby inducing sorafenib resistance in HCC (136). The gene discussed is PDHB; the disease is hepatocellular carcinoma.